HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival

Annals of Surgical Oncology

Volumn 18, Issue 7, 2011, Pages 2010-2017

  Thompson, Sarah K ^a   Sullivan, Thomas R ^a   Davies, Ruth ^b   Ruszkiewicz, Andrew R ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Division of Tissue Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 80051549783     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1554-1     Document Type: Article

References (37)

1. Thompson SK, Ruszkiewicz AR, Jamieson GG, Esterman A, Watson DI, Wijnhoven BP, et al. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol. 2008;15:3447-58.
2. Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539-48.
3. Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-24. (Pubitemid 351969725)
4. Boone J, van Hillegersberg R, Offerhaus GJA, van Diest PJ, Borel Rinkes IHM, ten Kate FJW. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22:496-504.
5. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER- 2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009;9:6.
6. Arrington AK, Dahlberg PS, Davydova J, Vickers SM, Yamamoto M. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. Surgery. 2009;146:213-9.
7. Dahlberg PS, Jacobson BA, Dahal G, Fink JM, Kratzke RA, Maddaus MA, et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg. 2004;78:1790-800. (Pubitemid 39423556)
8. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009;8: 2983-91.
9. Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS. 2009;117:737-45.
10. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/ neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35-9. (Pubitemid 30054384)
11. Bang YJ, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
12. Aly A, Jamieson GG, Pyragius M, Devitt PG. Antireflux anastamosis following oesophagectomy. ANZ J Surg. 2004;74:434-8.
13. Jamieson GG, Lamb PJ, Thompson SK. The role of lymphadenectomy in esophageal cancer. Ann Surg. 2009;250:206-9.
14. Graham AD, Faratian D, Rae F, Thomas JS. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2008;52:847-55. (Pubitemid 351724917)
15. Nitta H, Hauss-Wegrzniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol. 2008;3:41.
16. Scheuemann P, Hosch SB, Izbicki JR. Cytokeratins and other sensitive markers for esophageal cancer and metastases. Dis Esophagus. 2001;14:85-90. (Pubitemid 32951974)
17. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805. (Pubitemid 351724903)
18. Knight WE. A computer method for calculating Kendall's Tau with ungrouped data. J Am Stat Assoc. 1966;61:436-9.
19. Fléjou JF, Paraf F, Muzeau F, Fékété F, Hénin D, Jothy S, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol. 1994;47:23-6. (Pubitemid 24057743)
20. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbec N, Becker K, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer. 1994;73:1785-94. (Pubitemid 24101951)
21. Jankowski J, Coghill G, Hopwood D, Wormsley KG. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut. 1992;33:1033-8.
22. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of cerbB- 2 and c-erbB-3. World J Surg. 1999;23:1010-8. (Pubitemid 29451718)
23. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, et al. Immunohistochemical detection of p53 and cerbB- 2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 1997;23:30-5. (Pubitemid 27107489)
24. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993;54:213-9. (Pubitemid 23154884)
25. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erbB-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg. 1995;221:677-84.
26. Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus. Lab Invest. 2001;81:791-801. (Pubitemid 32553401)
27. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-9. (Pubitemid 44967957)
28. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol. 2002;118:60-6. (Pubitemid 34734253)
29. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-8. (Pubitemid 40309309)
30. Rosenberg CL. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J Clin Oncol. 2008;26:4856-8.
31. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839-42.
32. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-9.
33. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
34. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et. al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107-15. (Pubitemid 41076258)
35. Klein CA, Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res. 2009;69:5285-8.
36. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 2009;18:88-95.
37. Rauser S, Weis R, Braselman H, Feith M, Stein HJ, Langer R, et. al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res. 2007;13:5115-23. (Pubitemid 47502079)